The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2011

Filed:

Apr. 27, 2006
Applicants:

Chang-yuil Kang, Seoul, KR;

Yeonseok Chung, Seoul, KR;

Hyun-jeong Ko, Seoul, KR;

Yeon-jeong Kim, Changwon-si, KR;

Byung-seok Kim, Suwon-si, KR;

Sung-youl Ko, Bucheon-si, KR;

Inventors:

Chang-Yuil Kang, Seoul, KR;

Yeonseok Chung, Seoul, KR;

Hyun-Jeong Ko, Seoul, KR;

Yeon-Jeong Kim, Changwon-si, KR;

Byung-Seok Kim, Suwon-si, KR;

Sung-Youl Ko, Bucheon-si, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/02 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.


Find Patent Forward Citations

Loading…